Obesity is independently associated with worse patient-reported outcomes in women with systemic lupus erythematosus (SLE), including disease activity, depressive symptoms, pain and fatigue, according to new research findings presented at the 2017 ACR/ARHP Annual Meeting.

Obesity is a common comorbidity for people with SLE. While prior research shows that obesity can worsen systemic inflammation in the general population and contributes to worse disease-related outcomes in rheumatoid arthritis, its impact in lupus patients is not well established. A group of researchers at the University of California, San Francisco, conducted a study to determine whether excess adiposity, or too much body fat, in women with lupus is independently associated with worse patient-reported outcomes (PROs).

“We know from prior research that patients with lupus experience worse health-related quality of life and greater symptom burden compared to the general population, but we do not yet have a complete explanation for these worse experiences,” said Sarah Patterson, MD, a fellow in rheumatology at the University of California, San Francisco. “For example, neither disease-specific factors such as disease activity nor sociodemographic factors such as poverty fully explain the observed severity of these symptoms. And because we are interested in understanding how lifestyle factors such as exercise and weight management impact outcomes in lupus, we sought to determine if excess fat associates with worse PROs in this disease.”

Participants in the sample for the study were drawn from the Arthritis Body Composition and Disability (ABCD) Study. They had to be at least 18 years old, female and have a diagnosis of SLE verified by medical record review. The researchers calculated body-mass index (BMI). In addition, they calculated fat mass index (FMI), a measure of total fat mass adjusted for height, from whole dual X-ray absorptiometry (DXA) assessments. They used two established definitions of obesity: FMI greater than or equal to 13 kg/m^2 and BMI greater than or equal to 30 kg/m^2.

The dependent variables in the study included four validated PROs: disease activity measured according to the Systemic Lupus Activity Questionnaire (SLAQ), depressive symptoms according to the Center for Epidemiologic Studies Depression Scale (CES-D), pain using the Short Form 36 Health Survey (SF-36) Pain Subscale, and fatigue using the SF-36 Vitality Subscale. The researchers evaluated obesity’s association with these outcomes while controlling for potential confounders: age, race, education, income, smoking, disease duration, disease damage, and use of glucocorticoid medications such as prednisone.

The patients in the study’s sample of 148 patients were 65% white, 14% Asian and 13% African-American. Their mean age was 48. Of the lupus patients in the sample, 17% had a poverty-level income and 86% had education beyond high school. The mean disease duration in the sample was 16 years, and 45% of the patients had taken glucocorticoids.

When the researchers measured obesity among the lupus patients in the study, they found that 32% met the FMI definition of obesity and 30% met the BMI definition. Using a multivariate regression model, obesity as defined by FMI was associated with worse scores for each patient reported outcome: greater disease activity, higher levels of depressive symptoms, more pain and more fatigue. The researchers found the same relationship between obesity and these four outcomes after repeating the analyses using the BMI cut-off point for obesity.

The study’s results show that obesity is independently associated with worse outcomes in women with SLE, including increased disease activity, depressive symptoms, pain and fatigue.

“Our findings have important clinical implications because the PROs we measured, particularly pain and fatigue, are known to have profound effects on quality of life